HLA-C*17 in COVID-19 patients: Hints for associations with severe clinical outcome and cardiovascular risk

Immunol Lett. 2021 Jun:234:44-46. doi: 10.1016/j.imlet.2021.04.007. Epub 2021 Apr 24.

¹ Laboratory of Immunology and Biotherapy, Dept. Human Pathology, University of Messina, Italy; Clinical Pathology Unit - A.O.U. Policlinico G. Martino, Messina, Italy.
² Cell Factory Center UniMe, University of Messina, Italy.
³ Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Italy.
⁴ Clinical Pathology Unit - A.O.U. Policlinico G. Martino, Messina, Italy.
⁵ IRCCS Istituto Giannina Gaslini, Genoa, Italy.
⁶ Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
⁷ Laboratory of Immunology and Biotherapy, Dept. Human Pathology, University of Messina, Italy; Clinical Pathology Unit - A.O.U. Policlinico G. Martino, Messina, Italy; Cell Factory Center UniMe, University of Messina, Italy.
⁸ Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁹ Unit of Emergency Medicine - A.O.U. Policlinico G. Martino, Messina, Italy.
¹⁰ Department BIOMORF, Pulmonology, University of Messina, Italy.
¹¹ Department of Human Pathology, Unit of Anesthesiology, University of Messina, Italy.
¹² Laboratory of Immunology and Biotherapy, Dept. Human Pathology, University of Messina, Italy; Clinical Pathology Unit - A.O.U. Policlinico G. Martino, Messina, Italy; Cell Factory Center UniMe, University of Messina, Italy. Electronic address: guido.ferlazzo@unime.it.

No abstract available

Keywords: CD8+ cytotoxic T cells; COVID-19; Cardiovascular, SARS-CoV-2; HLA; KIR; Troponin-T.

Publication types